W. Zhang

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

Sreeneeranj Kasichayanula, Xuejun Liu, W. C. Shyu et al. · Diabetes Obesity and Metabolism · 2010 · 86 citations

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials

Yu Sunakawa, Sebastian Stintzing, Shu Cao et al. · Annals of Oncology · 2015 · 52 citations · Full text

Tumor-associated Macrophages, Oncology, Medicine +8

Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma

Georg Lurje, Hatim Husain, Derek G. Power et al. · Annals of Oncology · 2009 · 50 citations · Full text

Angiogenesis Pathway Genes, Angiogenesis, Tumor Heterogeneity +10

Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

Sreeneeranj Kasichayanula, Xuejun Liu, W. Zhang et al. · Diabetes Obesity and Metabolism · 2011 · 47 citations

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

Anthony B. El-Khoueiry, Ramesh K. Ramanathan, Dongyun Yang et al. · Investigational New Drugs · 2011 · 46 citations · Full text

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8